Outcomes
ADVERSE EVENTS, INFLAMMATION, SECONDARY
The primary outcome was change in glucose metabolism, as determined by the AUC for glucose excursion during the OGTT. Secondary outcomes related to glucose metabolism were changes in fasting glucose, insulin, HOMA-IR and HbA1c between baseline and follow-up after 28 days, as well as changes in glucose variability measured by CGM a week before and after intervention. Other secondary outcomes were the dynamic changes in gut bacteriome and virome populations following FFT or placebo intervention and the comparison of phage composition between lean donors and subjects with MetSyn. Finally, we assessed the safety of the FFT as determined by the occurrence of (serious) adverse events, physical exam and several blood parameters for renal and liver function and inflammation.